Stonepine Capital Management LLC Buys New Shares in Viracta Therapeutics, Inc. (NASDAQ:VIRX)

Stonepine Capital Management LLC purchased a new stake in shares of Viracta Therapeutics, Inc. (NASDAQ:VIRX) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 500,000 shares of the company’s stock, valued at approximately $116,000.

Viracta Therapeutics Price Performance

Shares of VIRX traded down $0.00 during mid-day trading on Wednesday, reaching $0.14. The company had a trading volume of 281,535 shares, compared to its average volume of 492,392. The company has a market capitalization of $5.56 million, a P/E ratio of -0.13 and a beta of 0.72. Viracta Therapeutics, Inc. has a twelve month low of $0.13 and a twelve month high of $1.31. The company’s 50-day moving average is $0.21 and its 200-day moving average is $0.40.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Leerink Partners lowered Viracta Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $5.00 to $3.00 in a report on Friday, August 16th. Royal Bank of Canada decreased their price target on shares of Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.